Impact of Smart Watch Mobile Application on Risk Treatment of CardioVascular Disease

Not Applicable

Conditions: Diseases of the circulatory system

Registration Number: KCT0008446

Lead Sponsor: Asan Medical Center

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 450

Inclusion Criteria

health insurance subscribers who are aged 20-54 years
24-hour ambulatory systolic BP 130-159 mmHg or serum LDL =130 mg/dl
Android smartphone users who can use ICT-based helathcare application
no use of anti-hypertensive or lipid-lowering drugs for =3 months prior to screening
subjects who are considered appropriate to be managed with lifestyle modification for 12 weeks
Subject who understands the purpose of the study and signs with informed consent form

Exclusion Criteria

24-hour ambulatory systolic or diastolic BP >160 mmHg or > 110 mmHg
underlying cardiovascular disease (ischemic heart disease, heart failure, aortic disease, valvular heart disease, arrhythmia, cardiomyopathy, etc.)
underlying cerebrovascular disease (stroke, cerebral infarction or hemorrhage, cerebral aneurysm, etc.)
chronic renal disease
peripheral vascular disease
pregnancy
secondary hypertension
atrial fibrillation or flutter
severe bradyarrhythmia
difficulty in BP measurement by smart watch
difference in systolic BP measurements from both arms > 10mmHg
life expectancy < 2 years
medical conditions that would limit adherence to participation (as confirmed by physicians)

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean change in 24-hour ambulatory systolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] in patients with hypertension [Category 1 & 3] Mean change in serum LDL-cholesterol level from baseline to 12 weeks [Time Frame: at 12-week follow-up] in patients with hyperlipidemia [Category 2 & 3]

Secondary Outcome Measures